Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Rheumatoid Arthritis
NCT00424346Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2006
- Primary completion
- Sep 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of canakinumab in rheumatoid arthritis (RA) (4 arms), sponsored by Novartis. Primary endpoint: American College of Rheumatology 50 Criteria Responders at 12 weeks. Started Nov 2006; status: completed.
02
Drugs
canakinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00424346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424346.